RA
XFOR icon

Royce & Associates’s X4 Pharmaceuticals XFOR Stock Holding History

Royce & Associates’s Portfolio XFOR Stock Details XFOR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-11,412
Closed -$476K – 919
2024
Q1 		$476K Sell
11,412
-1,533
-12% -$42.7K ﹤0.01% 796
2023
Q4 		$326K Buy
12,945
+8,978
+226% +$218K ﹤0.01% 819
2023
Q3 		$130K Buy
3,967
+2,184
+122% +$95.3K ﹤0.01% 888
2023
Q2 		$104K Buy
+1,783
New +$91.6K ﹤0.01% 898

Other funds holding XFOR

BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
KCM
Kingdon Capital Management New York $976M AUM 66.76% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Royce & Associates's XFOR Position: Q2 2024 in Review

Royce & Associates sold out of X4 Pharmaceuticals (XFOR) in Q2 2024, closing a stake of 11,412 shares — an estimated $476K sold.

Royce & Associates first reported a position in XFOR in Q2 2023 and held it in 4 quarters. The position peaked at $476K in Q1 2024. 98 funds tracked by Wall St. Rank hold XFOR as of Q2 2024.

  • Royce & Associates reported no remaining X4 Pharmaceuticals position as of Q2 2024 after selling out during the quarter.
  • Royce & Associates sold 11,412 X4 Pharmaceuticals shares in Q2 2024, an estimated $476K.
  • Royce & Associates first reported a position in X4 Pharmaceuticals in Q2 2023 and held it in 4 quarters.
  • Royce & Associates's X4 Pharmaceuticals position peaked at $476K in Q1 2024.
  • 98 funds tracked by Wall St. Rank held X4 Pharmaceuticals as of Q2 2024.

Based on Royce & Associates's 13F filing for Q2 2024, filed 13 Aug 2024.